© 2023 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
The award recognizes individuals and organizations who are making a difference in the myeloproliferative neoplasm community.
CURE Media Group, which reaches over 1 million patients, survivors and caregivers across an industry-leading multimedia platform devoted to cancer updates and research, is accepting nominations for the 2019 MPN Heroes® awards. This program honors organizations and individuals who have made a difference in the field of rare blood cancers known as myeloproliferative neoplasms (MPNs) by going above and beyond the standard of care, demonstrating leadership within the MPN community or a commitment to individual patients.
“We are excited to be accepting nominations for this year’s MPN Heroes Recognition Program,” said Michael J. Hennessy Jr., president of MJH Associates Inc., parent company of CURE Media Group. “We are proud to select and recognize another group of exceptional individuals who positively impact the MPN community each and every day.”
Nominations are accepted from the community at large. A panel of judges will review the nominations and pick the finalists and winners in two categories: Commitment to the Individual and Commitment to the Broader MPN Community. For more information, to submit a nomination and to learn more about this year’s rules, click here.
This year’s winners will be honored at the seventh annual MPN Heroes Celebration Event on December 6, 2019 at Sea World in Orlando, Florida.
The MPN Heroes Recognition Program is sponsored by Incyte Corporation and CURE Media Group, publishers of CURE® magazine. Incyte partners with CURE Media Group to support the program, with CURE® hosting the annual MPN Heroes Celebration Event recognizing heroes of the MPN community. Supporting the MPN community is an ongoing priority for Incyte, a global biopharmaceutical company that discovers and develops novel medicines to meet serious unmet medical needs in oncology and other diseases. Individuals or entities supported through funding or directed by Incyte are not eligible for consideration or recognition.
Understanding the Cancer Experience From the Outside Looking In
Educated Patient® Breast Cancer Summit at MBCC Treating Brain Metastases Presentation: March 4, 2023
Kisqali Plus Endocrine Therapy May Reduce Breast Cancer Recurrence Risk
Rybrevant Is Efficacious, Tolerable in EGFR Exon 20-Mutant Lung Cancer